Home

ADDUCE studying long-term safety in ADHD treatment

The Adduce studies (Attention deficit/hyperactivity disorder drugs use chronic effects) address the EU 7th framework Health work program “Adapting off-patent medicines to the specific needs of paediatric population”. Methylphenidate is a widely prescribed stimulant in ADHD. The ADDUCE studies will provide information on the long term side-effects in children and adolescents and cardiovascular effects in adults.

Click to read more

What is ADHD ?

Attention Deficit/Hyperactivity Disorder (ADHD) is one of the most common neurodevelopmental disorders in children, affecting approximately 5% of children in Europe.

What is ADDUCE ?

ADDUCE is an EU-research network focusing on the safety of treatment of ADHD in children and adolescents.

Declaration of possible Conflicts of Interest:

As experts in ADHD, some of the WP-leaders and/or site investigators are or have been involved in the recent past in giving advice to companies that invest in the search for new treatments for the disorder. Some receive(d) royalties for book chapters they have written on ADHD. Some have conducted trials with treatments that were still under development. None of them, however, are or have been shareholders in these companies or own patents. Activities such as the above may be seen as conflicts of interest and therefore are openly declared here. However, all investigators in the ADDUCE project regard themselves as independent researchers and thinkers.

News

The fifth ADDUCE Newsletter is now available!

Here, you can read about the finalisation of the project,

the European Medicines Agency and General Assembly meetings

and the dissemination of the results!

The fourth ADDUCE Newsletter is available!

In this newsletter, you can find some information on the final recruitment status of the 2 main studies:

- the prospective open-label methylphenidate pharmacovigilance study

- the long-term cardiascular effects of methylphenidate use

Also, you can read about the future plans of the project!

More than 1500 children, adolescents and adults across all Europe already took part in our study! Thanks to them, we have already gathered lots of information so we can know a lot more about methylphenidate than ever before!

Did you participate in the ADDUCE studies and are you curious about the latest news on the project?

Here you can find some information!

News for children, April 2015

News for adolescents, April 2015

News for parents, April 2015

The third ADDUCE Newsletter is available!

Events

16 - 19 OCTOBER 2016:

4rd EUNETHYDIS International Conference on ADHD, Berlin - Germany
from basis neuroscience to optimised clinical care

17 & 18 APRIL 2016:

ADDUCE Consortium meeting, London - UK

28 - 31 MAY 2015:

5th World Congress on ADHD: from Child to Adult Disorder, Glasgow - Scotland

20 & 21 APRIL 2015:

ADDUCE Consortium meeting, Salina - Italy

21 - 24 MAY 2014:

3rd EUNETHYDIS International Conference on ADHD, Istanbul - Turkey
ADHD and related disorders

19 & 20 MAY 2014:

ADDUCE Consortium meeting, Istanbul - Turkey

3 - 6 OCTOBER 2013:

23rd EUNETHYDIS Network Meeting, Prague Czech Republic
A meeting of the European Network of Hyperkinetic Disorders

6 - 9 JUNE 2013:

4th World Congress on ADHD: from Childhood to Adult Disease, Milan - Italy

4 & 5 JUNE 2013:

ADDUCE Consortium meeting, Milan - Italy

6 & 7 JUNE 2012:

ADDUCE Consortium meeting, Cagliari - Italy

23 MAY 2012:

2nd EUNETHYDIS International Conference on ADHD, Barcelona - Spain

The adhd-adduce logo
The ADDUCE Logo was developed by Matthew, a 14-year old boy who has ADHD. Matthew won the logo-design competition, organized by ADDISS, patient organization, UK
ADDISS homepage